

Neuropeptide Y


AND Drug Development

EDITED BY
GRUNDEMAR
BLOOM




ACADEMIC PRESS

$[^{125}\text{I}][\text{Leu}^{31}, \text{Pro}^{34}]\text{PYY}$



$[^{125}\text{I}]\text{PYY}_{3-36}$



Neuropeptide Y and Drug Development

This Page Intentionally Left Blank

Neuropeptide Y and Drug Development

edited by

Lars Grundemar

Department of Clinical Pharmacology,
Lund University Hospital,
S-221 85 Lund, Sweden

and

Stephen R. Bloom

Division of Endocrinology and Metabolism,
Royal Postgraduate Medical School,
University of London, Hammersmith Hospital,
London, UK



Academic Press

San Diego London Boston
New York Sydney Tokyo Toronto

This book is printed on acid-free paper.
Copyright © 1997 by ACADEMIC PRESS

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Academic Press, Inc.
525 B Street, Suite 1900, San Diego, California 92101-4495, USA
<http://www.apnet.com>

Academic Press Limited
24-28 Oval Road, London NW1 7DX, UK
<http://www.hbuk.co.uk/ap/>

ISBN 0-12-304990-3

A catalogue record for this book is available from the British Library

Typeset by Servis Filmsetting Ltd, Manchester
Printed in Great Britain by Hartnolls Ltd, Bodmin, Cornwall

97 98 99 00 01 02 EB 9 8 7 6 5 4 3 2 1

Front cover: Autoradiography showing the distribution of Y1-binding sites (top) and Y2-binding sites (bottom) at the level of the hippocampal formation of the monkey brain (see Dumont *et al.*, Chapter 4).

Back cover: *Serendipity* means the faculty of making fortunate discoveries by accident. The word comes from the Persian fairy tale 'The Three Princes of Serendip' (from Persian Sarandip, former name of Sri Lanka), the heroes of which were . . . 'always making discoveries, by accident and sagacity, of things they were not in quest of', and the expression serendipity was coined by the English author Horace Walpole in 1754. Serendipity is sometimes used in the pharmaceutical process of drug development in order to illustrate the random discovery of drugs and the often unpredictable ways they undergo to their final therapeutical niche (see also Preface).

Contents

Contributors	viii
Preface	x
1 Multiple receptors and multiple actions	1
<i>L. Grundemar</i>	
1.1 Multiple receptor types	1
1.2 Y1 receptors	2
1.3 Y2 receptors	3
1.4 Y3 receptors	5
1.5 PP1/Y receptors	5
1.6 Y5 receptors	10
1.7 Other receptors and targets	11
Acknowledgements	11
References	11
2 Central effects of neuropeptide Y with emphasis on its role in obesity and diabetes	15
<i>M. Turton, D. O'Shea and S.R. Bloom</i>	
2.1 Introduction	15
2.2 Pathways mediating the central effects of neuropeptide Y	18
2.3 Neuropeptide Y and the regulation of feeding	19
2.4 NPY and fat deposition	21
2.5 NPY and pituitary function	23
2.6 Other central effects of NPY	26
2.7 NPY and obesity	26
2.8 NPY, bulimia and anorexia nervosa	28
2.9 NPY and diabetes	29
2.10 Conclusion	30
References	30
3 Neuropeptide Y in sympathetic nerves: evidence for Y1 receptor mediated vascular control	41
<i>R.E. Malmström and J.M. Lundberg</i>	
3.1 Introduction	41
3.2 Prejunctional regulation of sympathetic transmitter release	42
3.3 NPY in plasma and its clearance	42

3.4	NPY in sympathetic neurotransmission	43
3.5	NPY and cardiovascular disorders	48
	References	49
4	Neuropeptide Y receptor types in mammalian brain: species differences and status in the human central nervous system	57
	<i>Y. Dumont, D. Jacques, J.-A. St-Pierre and R. Quirion</i>	
4.1	Introduction	57
4.2	Comparative distribution of NPY receptor types	59
4.3	Functional significance of various NPY receptor types	70
4.4	Conclusion	78
	Acknowledgements	79
	References	79
5	Extraordinary structural diversity of NPY-family receptors	87
	<i>D. Larhammar</i>	
5.1	Introduction	87
5.2	Y1 receptors	89
5.3	Y2 receptors	92
5.4	Pancreatic polypeptide receptors	96
5.5	Discussion	100
	Acknowledgements	103
	References	103
6	The importance of various parts of the NPY molecule for receptor recognition	107
	<i>A.G. Beck-Sickinger</i>	
6.1	Neuropeptide Y: sequence and secondary structure	107
6.2	Analogues for the characterization of the receptor types	108
6.3	Structure-activity relationships	110
6.4	A model of active conformations	118
	References	122
7	Peptide antagonists of neuropeptide Y: design, structure and pharmacological characterization	127
	<i>A.J. Daniels, D. Heyer and A. Spaltenstein</i>	
7.1	Background	127
7.2	Design of small peptide antagonists of neuropeptide Y	128
7.3	High-affinity peptide ligands	135
7.4	Peptide dimers as potent NPY antagonists	142
7.5	Pentapeptide dimers and multimers	149
	Conclusion	151
	Acknowledgements	151
	References	151

8	SR 120819A or the first generation of orally active Y1 receptor antagonists	157
	<i>C. Serradeil-Le Gal</i>	
8.1	Introduction	157
8.2	Discovery of SR 120819A	158
8.3	Biochemical profile of SR 120819A	159
8.4	<i>In vitro</i> functional studies with SR 120819A	164
8.5	Pharmacological profile of SR 120819A <i>in vivo</i>	164
8.6	Conclusion	168
	Acknowledgements	170
	References	170
9	BIBP 3226, a potent and selective neuropeptide Y Y1 receptor antagonist. Structure–activity studies and localization of the human Y1 receptor binding site	175
	<i>K. Rudolf, W. Eberlein, W. Engel, A.G. Beck-Sickinger, H. Wittneben, H.A. Wieland and H. Doods</i>	
9.1	Introduction	175
9.2	The design of the Y1-receptor antagonist BIBP 3226	176
9.3	The first structure–activity relationships	178
9.4	The receptor binding model of BIBP 3226	178
9.5	The pharmacological profile of BIBP 3226	185
9.6	Conclusions	188
	References	189
10	Discovery of neuropeptide Y receptor antagonists	191
	<i>A. Rabinovich, A. Mazurov, G. Krokhina, A. Ling, N. Livnah, Y. Hong, E. Valenzuela, V. Gregor, R. Feinstein, A. Polinsky, J.M. May, C. Hagaman and M.R. Brown</i>	
10.1	Introduction	191
10.2	Design and synthesis of peptide or peptide-like NPY receptor antagonists based on the analysis of structural analogs of NPY	192
10.3	Design and synthesis of non-peptide NPY receptor antagonists based on pharmacophore information derived from the analysis of peptide or peptide-like NPY receptor antagonists	195
10.4	Identification of non-peptide NPY receptor antagonists through the screening of combinational libraries	200
	References	201
	Index	203

A colour plate section appears between pages 148 and 149

Contributors

Annette G. Beck-Sickinger Federal Institute of Technology (ETH), Department of Pharmacy, Winterthurer Str. 190, CH-8057 Zurich, Switzerland

Stephen R. Bloom Division of Endocrinology and Metabolism, Royal Postgraduate Medical School, University of London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK

Marvin R. Brown Department of Pharmacology, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA

Alejandro J. Daniels GlaxoWellcome, Department of Metabolic Diseases, 3030 Cornwallis Road, Research Triangle Park, NC 27709, USA

Henri N. Doods Division of Preclinical Research, Dr Karl Thomae GmbH, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany

Yvan Dumont Department of Psychiatry, Douglas Hospital Research Centre, McGill University, 6875 LaSalle Blvd., Verdun, Quebec, Canada H4H 1R3

Wolfgang Eberlein Division of Preclinical Research, Dr Karl Thomae GmbH, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany

Wolfhard Engel Division of Preclinical Research, Dr Karl Thomae GmbH, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany

Robert Feinstein Department of Computational Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA

Vlad Gregor Department of Medicinal Chemistry, Alanex Corporation, 3550 General Atomics Courts, San Diego, CA 92121, USA

Lars Grundemar Department of Clinical Pharmacology, Lund University Hospital, S-221 85 Lund, Sweden

Cristin Hagaman Department of Pharmacology, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA

Dennis Heyer GlaxoWellcome, Department of Medicinal Chemistry, Research Triangle Park, NC 27709, USA

Yufeng Hong Department of Medicinal Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA

Danielle Jacques Department of Psychiatry, Douglas Hospital Research Centre, McGill University, 6875 LaSalle Blvd., Verdun, Quebec, Canada H4H 1R3

Galina Krokhina Department of Medicinal Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA

Dan Larhammar Department of Medical Pharmacology, Uppsala University, Box 593, S-751 24, Uppsala, Sweden

Anthony Ling Department of Medicinal Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA

Nurit Livnah Department of Medicinal Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA

- Jan M. Lundberg** Division of Pharmacology, Department of Physiology and Pharmacology, Karolinska Institute, S-171 77 Stockholm, Sweden
- Rickard E. Malmström** Division of Pharmacology, Department of Physiology and Pharmacology, Karolinska Institute, S-171 77 Stockholm, Sweden
- John Marvin May** Department of Pharmacology, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA
- Anatoly Mazurov** Department of Medicinal Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA
- Donal O'Shea** Division of Endocrinology and Metabolism, Royal Postgraduate Medical School, University of London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
- Alexander Polinsky** Department of Computational Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA
- Rémi Quirion** Department of Psychiatry, Douglas Research Centre, McGill University, 6875 LaSalle Blvd., Verdun, Quebec, Canada H4H 1R3
- Alexandr Rabinovich** Department of Medical Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA
- Klaus Rudolf** Division of Preclinical Research, Dr Karl Thomae GmbH, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany
- Claudine Serradeil-Le Gal** Sanofi Recherche, Exploratory Research Department, 195 Route d'Espagne, 31036 Toulouse Cedex, France
- Andrew Spaltenstein** GlaxoWellcome, Department of Medicinal Chemistry, Research Triangle Park, NC 27709, USA
- Jacques-André St-Pierre** Department of Psychiatry, Douglas Research Centre, McGill University, 6875 LaSalle Blvd., Verdun, Quebec, Canada H4H 1R3
- M.D. Turton** Division of Endocrinology and Metabolism, Royal Postgraduate Medical School, University of London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
- Eileen Valenzuela** Department of Medicinal Chemistry, Alanex Corporation, 3550 General Atomics Court, San Diego, CA 92121, USA
- Heike A. Wieland** Division of Preclinical Research, Dr Karl Thomae GmbH., Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany
- Helmut Wittneben** Division of Preclinical Research, Dr Karl Thomae GmbH, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany

Preface: the search for new therapeutic approaches

'New beauty pill – lose pounds on a once-a-day tablet'. Such newspaper headlines announce yet another spurious breakthrough in a field over-ripe with expectation. The first genuinely safe and effective oral therapy that can be taken over decades will be the world's first trillion dollar drug.

Neuropeptide Y (NPY) causes hypertension, increased food intake, inhibits sexual function, inhibits growth and causes sedation, amongst several other actions. The mythical NPY-blocked man would be thin, tall, vivacious and very interested in sex. Certainly a profitable image.

More seriously, many drugs acting on neuro-hormonal targets modulate the transmission in monoamine transmitter systems, like dopamine, noradrenaline and serotonin. These drugs include antiparkinsonism drugs, neuroleptics, antidepressants and antihypertensive drugs and the principles of how these drugs act are well understood. The launch of such therapeutics in the 1950s and 1960s represented breakthrough achievements in the treatment of many disorders. Ironically, several of these drugs were introduced clinically before they were recognized as important neuropharmacological tools with which it was possible to delineate the significance of monoamines as transmitters in various physiological processes and pathological states.

Developments during the last two decades resulted in the discovery of many novel transmitter types, such as the neuropeptides and polypeptide hormones. Although, there are obvious differences between monoamine transmitters and peptide transmitters in molecular size and processing, monoamines and neuropeptides have many features in common. In fact, transmitters from both chemical groups are often co-stored and co-released from nerve terminals, act on the same neurons through activation of distinct and specific receptors, and affect the same ion channels and signal transduction pathways. Vasopressin and oxytocin analogues, ACTH and some other polypeptide agonists have been used clinically in substitution therapy and other conditions for a number of years. However, for clinical use, peptides suffer from poor pharmacokinetic properties, such as low oral bioavailability and rapid degradation.

Most neuropeptides, like many other neurotransmitters, activate G-protein-coupled receptors. Characteristic of this receptor superfamily are the seven transmembraneous spanning domains, which are linked together by extracellular and intracellular loops, of which the third intracellular loop is known to modulate the function of the G-protein.

It has sometimes been argued that neuropeptides act merely as modulators or that they are redundant in mammalian physiology. The rapidly increasing body of knowledge about the various neuro/hormonal peptide systems in the brain and periphery suggests that many of them indeed play a role in controlling important physiological processes and that several of the peptide receptors are promising therapeutic targets. Although the cloning of monoamine receptors has shown that they consist of many

more receptor types than expected, the multitude of neuropeptides and their many receptors offer a large number of additional and attractive drug targets. Much effort has been taken to identify the pharmacophore of several neuropeptides (and other transmitters) and the parts of the receptor that recognize the ligand. This knowledge, in addition to high throughput screening techniques, has been beneficial in the search for non-peptide ligands acting on peptide receptors. Thus, it appears that the obstacle of constructing non-peptide receptor antagonists can be overcome and, for example, the angiotensin II (AT1)-receptor antagonist losartan has recently been approved for use in hypertension in several countries. In many neuropeptide receptor systems there is a search for new therapeutic approaches and they include, for instance, modulation of opioid-, tachykinin-, cholecystikinin-, neurotensin- and NPY receptor systems.

NPY is a member of a family of peptides, which also includes the structurally related gut hormones peptide YY (PYY) and pancreatic polypeptide (PP). Since the isolation and identification of NPY in 1982, several thousand publications have examined various aspects of this neuropeptide. NPY has received much attention because it is ubiquitous in the mammalian nervous system and because numerous physiological functions in the brain and periphery have been attributed to the peptide. Interestingly, the NPY molecule is remarkably well conserved through evolution and appears to be the oldest member in this peptide family, suggestive for an important physiological role of this peptide. For instance, NPY is one of the most potent stimuli of food intake known and it occurs in hypothalamic nuclei known to regulate feeding behaviour. The peptide has been implicated in disorders related to altered energy balance, like obesity and anorexia/bulimia. In the periphery, the peptide occurs in perivascular sympathetic nerve fibres and it is co-released with noradrenaline upon high sympathetic nerve activity. NPY is a potent vasoconstrictor, being several orders of magnitude more potent than noradrenaline and the peptide has been implicated in various cardiovascular disorders.

Very recently Erickson and coworkers presented results on functional consequences of embryonic NPY gene knock out in mice (*Nature* (1996) **381**, 415–418). Such mutated mice appeared to have a normal food intake and body weight, but were more sensitive to weight loss following leptin treatment. Besides an increased susceptibility to epileptic seizures, these mice did not show any other gross anomalies and were able to reproduce. These seemingly disappointing results on the importance of NPY in feeding behaviour and other physiological processes should naturally be interpreted with caution. The fundamental system(s) that regulates feeding behaviour consists of many parallel neurotransmitter pathways in a highly complex manner. Conceivably, these results illustrate an embryonic dynamic plasticity, resulting in compensatory mechanisms that are not necessarily apparent in the mature individual. A temporary blockade of NYP effects in the adult animal is probably required to elucidate this issue.

NPY and its congeners act at multiple receptor types, belonging to the family of G-protein-coupled receptors. Several of the NPY-receptor types are promising targets for drug development and many pharmaceutical companies are carrying out research

on this peptide. The rational approach of designing non-peptide receptor antagonists by identifying peptide pharmacophores using minimization of polypeptides, followed by the construction of small non-peptide ligands has generated useful NPY-receptor antagonists. The most promising areas for application of NPY-receptor antagonists appear to be in the treatment of obesity and perhaps cardiovascular disorders.

An irrational but important factor in the drug discovery and development is serendipity. Often it is difficult to predict the clinical value of a drug candidate based solely on recognized pharmacological effects. For instance, who could have foreseen the widespread use of β -adrenoceptor antagonists in the treatment of hypertension and other cardiovascular disorders? The pharmacological history of drug development illustrates the fact that important breakthroughs are often associated with accidental findings, and that many drugs on the market are used today on indications quite distinct from those originally predicted. In the case of NPY, it is important first to elucidate the physiological and pathophysiological significance of the peptide. With the use of newly developed NPY receptor antagonists, such knowledge is about to emerge. This knowledge can then be used to increase our understanding of how these agents can best be used in a clinical context. It is not unlikely that future studies will discover novel clinical applications of NPY-receptor antagonists distinct from those already proposed. However, an area that is not discussed in this book is the possible utility of NPY-receptor agonists, which perhaps may be beneficial in nasal congestion, diarrhoea, anxiety, epilepsy and pain. More studies are required to assess the role of NPY in these conditions and it is generally difficult to construct non-peptide agonists with acceptable pharmacodynamic and kinetic properties compared with non-peptide antagonists.

Previous books about NPY have been either proceedings from symposia and meetings, or have aimed to cover wide aspects of the whole NPY/PYY/PP family. This book discusses why NPY-receptors represent promising therapeutic targets and describes the latest progress in NPY pharmacology, molecular biology of receptors, characteristics of newly developed NPY-receptor antagonists, and focuses on physiological systems where the use of such antagonists might offer new therapeutic approaches. Efforts have been made to link basic experimental knowledge with areas of possible clinical importance.

Lars Grundemar, Department of Clinical Pharmacology, Lund University
Hospital, Sweden.

Stephen R. Bloom, Division of Endocrinology and Metabolism, University of
London, Hammersmith Hospital, Du Cane Road, London, UK.